Incipient and subclinical tuberculosis: A clinical review of early stages and progression of infection

Clinical Microbiology Reviews

Volumn 31, Issue 4, 2018, Pages

  Drain, Paul K ^a   Bajema, Kristina L ^a   Dowdy, David ^b   Dheda, Keertan ^c   Naidoo, Kogieleum ^d,h   Schumacher, Samuel G ^e   Ma, Shuyi ^a,f   Meermeier, Erin ^g   Lewinsohn, David M ^g   Sherman, David R ^a,f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d Foundation for Innovative New Diagnostics ^*  (South Africa)

^e FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

^f SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

Mycobacterium tuberculosis; Tuberculosis

Indexed keywords

BEDAQUILINE; BIOLOGICAL MARKER; CYTOKINE; DELAMANID; ISONIAZID; LINEZOLID; SUTEZOLID; TRANSCRIPTOME; TUBERCULOSTATIC AGENT;

CD4 LYMPHOCYTE COUNT; CELL HETEROGENEITY; COMMUNICABLE DISEASE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; DRUG INTERACTION; FOLLOW UP; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMORAL IMMUNITY; IMMUNE RESPONSE; LUNG TUBERCULOSIS; MICROENVIRONMENT; MYCOBACTERIUM TUBERCULOSIS; PHAGOCYTOSIS; PHENOTYPIC VARIATION; POSITRON EMISSION TOMOGRAPHY; PUBLIC HEALTH; REVIEW; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; HUMAN; IMMUNOLOGY; LATENT TUBERCULOSIS; PATHOLOGY;

ANTITUBERCULAR AGENTS; HUMANS; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 85052144789     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00021-18     Document Type: Review

References (249)

1. World Health Organization. 2016. Global tuberculosis report. World Health Organization, Geneva, Switzerland.
2. Houben RM, Dodd PJ. 2016. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med 13:e1002152. https://doi.org/10.1371/journal.pmed.1002152.
3. World Health Organization. 2014. The end TB strategy. World Health Organization, Geneva, Switzerland.
4. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, Ginsberg A, Swaminathan S, Spigelman M, Getahun H, Menzies D, Raviglione M. 2016. Tuberculosis. Nat Rev Dis Primers 2:16076. https://doi.org/10.1038/nrdp.2016.76.
5. Cadena AM, Fortune SM, Flynn JL. 2017. Heterogeneity in tuberculosis. Nat Rev Immunol 17:691–702. https://doi.org/10.1038/nri.2017.69.
6. Barry CE, III, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. 2009. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7:845–855. https://doi.org/10.1038/nrmicro2236.
7. Schwander S, Dheda K. 2011. Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection. Am J Respir Crit Care Med 183:696–707. https://doi.org/10.1164/rccm.201006-0963PP.
8. Achkar JM, Jenny-Avital ER. 2011. Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response. J Infect Dis 204(Suppl 4):S1179–S1186. https://doi.org/10.1093/infdis/jir451.
9. World Health Organization. 2017. Consensus meeting report: development of a target product profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease. World Health Organization, Geneva, Switzerland.
10. World Health Organization. 2015. Guidelines on the management of latent tuberculosis infection. World Health Organization, Geneva, Switzerland.
11. World Health Organization. 2018. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. World Health Organization, Geneva, Switzerland.
12. Dheda K, Barry CE, III, Maartens G. 2016. Tuberculosis. Lancet 387: 1211–1226. https://doi.org/10.1016/S0140-6736(15)00151-8.
13. World Health Organization. 2010. Treatment of tuberculosis guidelines, 4th ed. World Health Organization, Geneva, Switzerland.
14. Lopez B, Aguilar D, Orozco H, Burger M, Espitia C, Ritacco V, Barrera L, Kremer K, Hernandez-Pando R, Huygen K, van Soolingen D. 2003. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin Exp Immunol 133:30–37. https://doi.org/10.1046/j.1365-2249.2003.02171.x.
15. Gagneux S, DeRiemer K, Van T, Kato-Maeda M, de Jong BC, Narayanan S, Nicol M, Niemann S, Kremer K, Gutierrez MC, Hilty M, Hopewell PC, Small PM. 2006. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 103:2869–2873. https://doi.org/10.1073/pnas.0511240103.
16. Coscolla M, Gagneux S. 2010. Does M. tuberculosis genomic diversity explain disease diversity? Drug Discov Today Dis Mech 7:e43–e59. https://doi.org/10.1016/j.ddmec.2010.09.004.
17. Tientcheu LD, Koch A, Ndengane M, Andoseh G, Kampmann B, Wilkinson RJ. 2017. Immunological consequences of strain variation within the Mycobacterium tuberculosis complex. Eur J Immunol 47:432–445. https://doi.org/10.1002/eji.201646562.
18. Coscolla M, Gagneux S. 2014. Consequences of genomic diversity in Mycobacterium tuberculosis. Semin Immunol 26:431–444. https://doi.org/10.1016/j.smim.2014.09.012.
19. Nebenzahl-Guimaraes H, Yimer SA, Holm-Hansen C, de Beer J, Brosch R, van Soolingen D. 2016. Genomic characterization of Mycobacterium tuberculosis lineage 7 and a proposed name: ‘Aethiops vetus’. Microb Genom 2:e000063. https://doi.org/10.1099/mgen.0.000063.
20. Gagneux S. 2018. Ecology and evolution of Mycobacterium tuberculosis. Nat Rev Microbiol 16:202–213. https://doi.org/10.1038/nrmicro. 2018.8.
21. Firdessa R, Berg S, Hailu E, Schelling E, Gumi B, Erenso G, Gadisa E, Kiros T, Habtamu M, Hussein J, Zinsstag J, Robertson BD, Ameni G, Lohan AJ, Loftus B, Comas I, Gagneux S, Tschopp R, Yamuah L, Hewinson G, Gordon SV, Young DB, Aseffa A. 2013. Mycobacterial lineages causing pulmonary and extrapulmonary tuberculosis, Ethiopia. Emerg Infect Dis 19:460–463. https://doi.org/10.3201/eid1903.120256.
22. Ribeiro SC, Gomes LL, Amaral EP, Andrade MR, Almeida FM, Rezende AL, Lanes VR, Carvalho EC, Suffys PN, Mokrousov I, Lasunskaia EB. 2014. Mycobacterium tuberculosis strains of the modern sublineage of the Beijing family are more likely to display increased virulence than strains of the ancient sublineage. J Clin Microbiol 52:2615–2624. https://doi.org/10.1128/JCM.00498-14.
23. Portevin D, Gagneux S, Comas I, Young D. 2011. Human macrophage responses to clinical isolates from the Mycobacterium tuberculosis complex discriminate between ancient and modern lineages. PLoS Pathog 7:e1001307. https://doi.org/10.1371/journal.ppat.1001307.
24. Reiling N, Homolka S, Walter K, Brandenburg J, Niwinski L, Ernst M, Herzmann C, Lange C, Diel R, Ehlers S, Niemann S. 2013. Clade-specific virulence patterns of Mycobacterium tuberculosis complex strains in human primary macrophages and aerogenically infected mice. mBio 4:e00250-13. https://doi.org/10.1128/mBio.00250-13.
25. Tsenova L, Ellison E, Harbacheuski R, Moreira AL, Kurepina N, Reed MB, Mathema B, Barry CE, III, Kaplan G. 2005. Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J Infect Dis 192:98–106. https://doi.org/10.1086/430614.
26. Manca C, Tsenova L, Barry CE, III, Bergtold A, Freeman S, Haslett PA, Musser JM, Freedman VH, Kaplan G. 1999. Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J Immunol 162: 6740–6746.
27. Manca C, Tsenova L, Bergtold A, Freeman S, Tovey M, Musser JM, Barry CE, III, Freedman VH, Kaplan G. 2001. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta. Proc Natl Acad Sci U S A 98:5752–5757. https://doi.org/10.1073/pnas.091096998.
28. Reed MB, Domenech P, Manca C, Su H, Barczak AK, Kreiswirth BN, Kaplan G, Barry CE, III. 2004. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431:84–87. https://doi.org/10.1038/nature02837.
29. Manca C, Reed MB, Freeman S, Mathema B, Kreiswirth B, Barry CE, III, Kaplan G. 2004. Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis. Infect Immun 72: 5511–5514. https://doi.org/10.1128/IAI.72.9.5511-5514.2004.
30. Via LE, Weiner DM, Schimel D, Lin PL, Dayao E, Tankersley SL, Cai Y, Coleman MT, Tomko J, Paripati P, Orandle M, Kastenmayer RJ, Tartakovsky M, Rosenthal A, Portevin D, Eum SY, Lahouar S, Gagneux S, Young DB, Flynn JL, Barry CE, III. 2013. Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus). Infect Immun 81: 2909–2919. https://doi.org/10.1128/IAI.00632-13.
31. Tientcheu LD, Sutherland JS, de Jong BC, Kampmann B, Jafali J, Adetifa IM, Antonio M, Dockrell HM, Ota MO. 2014. Differences in T-cell responses between Mycobacterium tuberculosis and Mycobacterium africanum-infected patients. Eur J Immunol 44:1387–1398. https://doi.org/10.1002/eji.201343956.
32. de Jong BC, Hill PC, Aiken A, Awine T, Antonio M, Adetifa IM, Jackson-Sillah DJ, Fox A, Deriemer K, Gagneux S, Borgdorff MW, McAdam KP, Corrah T, Small PM, Adegbola RA. 2008. Progression to active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage in The Gambia. J Infect Dis 198:1037–1043. https://doi.org/10.1086/591504.
33. Dutta NK, Karakousis PC. 2014. Latent tuberculosis infection: myths, models, and molecular mechanisms. Microbiol Mol Biol Rev 78: 343–371. https://doi.org/10.1128/MMBR.00010-14.
34. Dhar N, McKinney J, Manina G. 2016. Phenotypic heterogeneity in Mycobacterium tuberculosis. Microbiol Spectr 4:TBTB2–0021-2016. https://doi.org/10.1128/microbiolspec.TBTB2-0021-2016.
35. Lenaerts A, Barry CE, III, Dartois V. 2015. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev 264:288–307. https://doi.org/10.1111/imr.12252.
36. Wang C. 1916. An experimental study of latent tuberculosis. Lancet 188:417–419. https://doi.org/10.1016/S0140-6736(00)58936-3.
37. Loomis H. 1890. Some facts in the etiology of tuberculosis, evidenced by thirty autopsies and experiments upon animals. Med Rec (1866-1922) 38:689.
38. Opie E. 1927. Tubercle bacilli in latent tuberculous lesions and in the lung tissue without tuberculous lesions. Arch Pathol Lab Med 4:1–21.
39. Neyrolles O, Hernandez-Pando R, Pietri-Rouxel F, Fornes P, Tailleux L, Barrios Payan JA, Pivert E, Bordat Y, Aguilar D, Prevost MC, Petit C, Gicquel B. 2006. Is adipose tissue a place for Mycobacterium tubercu- losis persistence? PLoS One 1:e43. https://doi.org/10.1371/journal.pone.0000043.
40. Esmail H, Lai RP, Lesosky M, Wilkinson KA, Graham CM, Coussens AK, Oni T, Warwick JM, Said-Hartley Q, Koegelenberg CF, Walzl G, Flynn JL, Young DB, Barry CE, III, O’Garra A, Wilkinson RJ. 2016. Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[(18)F] fluoro-D-glucose positron emission and computed tomography. Nat Med 22:1090–1093. https://doi.org/10.1038/nm.4161.
41. Schnappinger D, Ehrt S. 2016. A broader spectrum of tuberculosis. Nat Med 22:1076–1077. https://doi.org/10.1038/nm.4186.
42. Gengenbacher M, Kaufmann SH. 2012. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev 36:514–532. https://doi.org/10.1111/j.1574-6976.2012.00331.x.
43. Lipworth S, Hammond RJ, Baron VO, Hu Y, Coates A, Gillespie SH. 2016. Defining dormancy in mycobacterial disease. Tuberculosis (Edinb) 99: 131–142. https://doi.org/10.1016/j.tube.2016.05.006.
44. Albrethsen J, Agner J, Piersma SR, Hojrup P, Pham TV, Weldingh K, Jimenez CR, Andersen P, Rosenkrands I. 2013. Proteomic profiling of Mycobacterium tuberculosis identifies nutrient-starvation-responsive toxin-antitoxin systems. Mol Cell Proteomics 12:1180–1191. https://doi.org/10.1074/mcp.M112.018846.
45. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. 2002. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 43: 717–731. https://doi.org/10.1046/j.1365-2958.2002.02779.x.
46. Schubert OT, Ludwig C, Kogadeeva M, Zimmermann M, Rosenberger G, Gengenbacher M, Gillet LC, Collins BC, Rost HL, Kaufmann SH, Sauer U, Aebersold R. 2015. Absolute proteome composition and dynamics during dormancy and resuscitation of Mycobacterium tuberculosis. Cell Host Microbe 18:96–108. https://doi.org/10.1016/j.chom.2015.06.001.
47. Rustad TR, Harrell MI, Liao R, Sherman DR. 2008. The enduring hypoxic response of Mycobacterium tuberculosis. PLoS One 3:e1502. https://doi.org/10.1371/journal.pone.0001502.
48. Boshoff HI, Barry CE, III. 2005. Tuberculosis—metabolism and respiration in the absence of growth. Nat Rev Microbiol 3:70–80. https://doi.org/10.1038/nrmicro1065.
49. Shi L, Sohaskey CD, Kana BD, Dawes S, North RJ, Mizrahi V, Gennaro ML. 2005. Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration. Proc Natl Acad Sci U S A 102:15629–15634. https://doi.org/10.1073/pnas.0507850102.
50. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, Sherman DR, Schoolnik GK. 2003. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 198:705–713. https://doi.org/10.1084/jem.20030205.
51. Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrell MI, Schoolnik GK. 2001. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-crystallin. Proc Natl Acad Sci U S A 98:7534–7539. https://doi.org/10.1073/pnas.121172498.
52. Galagan JE, Minch K, Peterson M, Lyubetskaya A, Azizi E, Sweet L, Gomes A, Rustad T, Dolganov G, Glotova I, Abeel T, Mahwinney C, Kennedy AD, Allard R, Brabant W, Krueger A, Jaini S, Honda B, Yu WH, Hickey MJ, Zucker J, Garay C, Weiner B, Sisk P, Stolte C, Winkler JK, Van de Peer Y, Iazzetti P, Camacho D, Dreyfuss J, Liu Y, Dorhoi A, Mollenkopf HJ, Drogaris P, Lamontagne J, Zhou Y, Piquenot J, Park ST, Raman S, Kaufmann SH, Mohney RP, Chelsky D, Moody DB, Sherman DR, Schoolnik GK. 2013. The Mycobacterium tuberculosis regulatory network and hypoxia. Nature 499:178–183. https://doi.org/10.1038/nature12337.
53. Chauhan R, Ravi J, Datta P, Chen T, Schnappinger D, Bassler KE, Balazsi G, Gennaro ML. 2016. Reconstruction and topological characterization of the sigma factor regulatory network of Mycobacterium tuberculosis. Nat Commun 7:11062. https://doi.org/10.1038/ncomms11062.
54. Sanyal S, Banerjee SK, Banerjee R, Mukhopadhyay J, Kundu M. 2013. Polyphosphate kinase 1, a central node in the stress response network of Mycobacterium tuberculosis, connects the two-component systems MprAB and SenX3-RegX3 and the extracytoplasmic function sigma factor, sigma E. Microbiology 159:2074–2086. https://doi.org/10.1099/mic.0.068452-0.
55. Dutta NK, Mehra S, Martinez AN, Alvarez X, Renner NA, Morici LA, Pahar B, Maclean AG, Lackner AA, Kaushal D. 2012. The stress-response factor SigH modulates the interaction between Mycobacterium tuberculosis and host phagocytes. PLoS One 7:e28958. https://doi.org/10.1371/journal.pone.0028958.
56. Fontan PA, Voskuil MI, Gomez M, Tan D, Pardini M, Manganelli R, Fattorini L, Schoolnik GK, Smith I. 2009. The Mycobacterium tuberculosis sigma factor sigmaB is required for full response to cell envelope stress and hypoxia in vitro, but it is dispensable for in vivo growth. J Bacteriol 191:5628–5633. https://doi.org/10.1128/JB.00510-09.
57. Ortega C, Liao R, Anderson LN, Rustad T, Ollodart AR, Wright AT, Sherman DR, Grundner C. 2014. Mycobacterium tuberculosis Ser/Thr protein kinase B mediates an oxygen-dependent replication switch. PLoS Biol 12:e1001746. https://doi.org/10.1371/journal.pbio.1001746.
58. Sureka K, Dey S, Datta P, Singh AK, Dasgupta A, Rodrigue S, Basu J, Kundu M. 2007. Polyphosphate kinase is involved in stress-induced mprAB-sigE-rel signalling in mycobacteria. Mol Microbiol 65:261–276. https://doi.org/10.1111/j.1365-2958.2007.05814.x.
59. Avarbock D, Avarbock A, Rubin H. 2000. Differential regulation of opposing RelMtb activities by the aminoacylation state of a tRNA·ribosome·mRNA·RelMtb complex. Biochemistry 39:11640–11648. https://doi.org/10.1021/bi001256k.
60. Sajish M, Tiwari D, Rananaware D, Nandicoori VK, Prakash B. 2007. A charge reversal differentiates (p)ppGpp synthesis by monofunctional and bifunctional Rel proteins. J Biol Chem 282:34977–34983. https://doi.org/10.1074/jbc.M704828200.
61. Manina G, Dhar N, McKinney JD. 2015. Stress and host immunity amplify Mycobacterium tuberculosis phenotypic heterogeneity and induce nongrowing metabolically active forms. Cell Host Microbe 17: 32–46. https://doi.org/10.1016/j.chom.2014.11.016.
62. Mouton JM, Helaine S, Holden DW, Sampson SL. 2016. Elucidating population-wide mycobacterial replication dynamics at the single-cell level. Microbiology 162:966–978. https://doi.org/10.1099/mic.0.000288.
63. Dartois V, Saito K, Warrier T, Nathan C. 2016. New evidence for the complexity of the population structure of Mycobacterium tuberculosis increases the diagnostic and biologic challenges. Am J Respir Crit Care Med 194:1448–1451. https://doi.org/10.1164/rccm.201607-1431ED.
64. Chengalroyen MD, Beukes GM, Gordhan BG, Streicher EM, Churchyard G, Hafner R, Warren R, Otwombe K, Martinson N, Kana BD. 2016. Detection and quantification of differentially culturable tubercle bacteria in sputum from patients with tuberculosis. Am J Respir Crit Care Med 194:1532–1540. https://doi.org/10.1164/rccm.201604-0769OC.
65. Lin PL, Ford CB, Coleman MT, Myers AJ, Gawande R, Ioerger T, Sacchet-tini J, Fortune SM, Flynn JL. 2014. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med 20:75–79. https://doi.org/10.1038/nm.3412.
66. Hawn TR, Shah JA, Kalman D. 2015. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics. Immunol Rev 264:344–362. https://doi.org/10.1111/imr.12255.
67. Scriba TJ, Penn-Nicholson A, Shankar S, Hraha T, Thompson EG, Sterling D, Nemes E, Darboe F, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Johnson JL, Boom WH, Hatherill M, Valvo J, De Groote MA, Ochsner UA, Aderem A, Hanekom WA, Zak DE. 2017. Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease. PLoS Pathog 13:e1006687. https://doi.org/10.1371/journal.ppat.1006687.
68. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, Wilkinson KA, Banchereau R, Skinner J, Wilkinson RJ, Quinn C, Blankenship D, Dhawan R, Cush JJ, Mejias A, Ramilo O, Kon OM, Pascual V, Banchereau J, Chaussabel D, O’Garra A. 2010. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466:973–977. https://doi.org/10.1038/nature09247.
69. Kaforou M, Wright VJ, Oni T, French N, Anderson ST, Bangani N, Banwell CM, Brent AJ, Crampin AC, Dockrell HM, Eley B, Heyderman RS, Hibberd ML, Kern F, Langford PR, Ling L, Mendelson M, Ottenhoff TH, Zgambo F, Wilkinson RJ, Coin LJ, Levin M. 2013. Detection of tuberculosis in HIV-infected and-uninfected African adults using whole blood RNA expression signatures: a case-control study. PLoS Med 10:e1001538. https://doi.org/10.1371/journal.pmed.1001538.
70. Bloom CI, Graham CM, Berry MP, Rozakeas F, Redford PS, Wang Y, Xu Z, Wilkinson KA, Wilkinson RJ, Kendrick Y, Devouassoux G, Ferry T, Miyara M, Bouvry D, Valeyre D, Gorochov G, Blankenship D, Saadatian M, Vanhems P, Beynon H, Vancheeswaran R, Wickremasinghe M, Chaussabel D, Banchereau J, Pascual V, Ho LP, Lipman M, O’Garra A. 2013. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One 8:e70630. https://doi.org/10.1371/journal.pone.0070630.
71. Anderson ST, Kaforou M, Brent AJ, Wright VJ, Banwell CM, Chagaluka G, Crampin AC, Dockrell HM, French N, Hamilton MS, Hibberd ML, Kern F, Langford PR, Ling L, Mlotha R, Ottenhoff THM, Pienaar S, Pillay V, Scott JAG, Twahir H, Wilkinson RJ, Coin LJ, Heyderman RS, Levin M, Eley B. 2014. Diagnosis of childhood tuberculosis and host RNA expression in Africa. N Engl J Med 370:1712–1723. https://doi.org/10.1056/NEJMoa1303657.
72. Phuah JY, Mattila JT, Lin PL, Flynn JL. 2012. Activated B cells in the granulomas of nonhuman primates infected with Mycobacterium tuberculosis. Am J Pathol 181:508–514. https://doi.org/10.1016/j.ajpath.2012.05.009.
73. Torrado E, Fountain JJ, Robinson RT, Martino CA, Pearl JE, Rangel-Moreno J, Tighe M, Dunn R, Cooper AM. 2013. Differential and site specific impact of B cells in the protective immune response to Mycobacterium tuberculosis in the mouse. PLoS One 8:e61681. https://doi.org/10.1371/journal.pone.0061681.
74. Lu LL, Chung AW, Rosebrock TR, Ghebremichael M, Yu WH, Grace PS, Schoen MK, Tafesse F, Martin C, Leung V, Mahan AE, Sips M, Kumar MP, Tedesco J, Robinson H, Tkachenko E, Draghi M, Freedberg KJ, Streeck H, Suscovich TJ, Lauffenburger DA, Restrepo BI, Day C, Fortune SM, Alter G. 2016. A functional role for antibodies in tuberculosis. Cell 167: 433.e14–443.e14. https://doi.org/10.1016/j.cell.2016.08.072.
75. Wanchu A, Dong Y, Sethi S, Myneedu VP, Nadas A, Liu Z, Belisle J, Laal S. 2008. Biomarkers for clinical and incipient tuberculosis: performance in a TB-endemic country. PLoS One 3:e2071. https://doi.org/10.1371/journal.pone.0002071.
76. Bulut Y, Michelsen KS, Hayrapetian L, Naiki Y, Spallek R, Singh M, Arditi M. 2005. Mycobacterium tuberculosis heat shock proteins use diverse Toll-like receptor pathways to activate pro-inflammatory signals. J Biol Chem 280:20961–20967. https://doi.org/10.1074/jbc.M411379200.
77. Andrews JR, Nemes E, Tameris M, Landry BS, Mahomed H, McClain JB, Fletcher HA, Hanekom WA, Wood R, McShane H, Scriba TJ, Hatherill M. 2017. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respir Med 5:282–290. https://doi.org/10.1016/S2213-2600(17)30060-7.
78. Millington KA, Innes JA, Hackforth S, Hinks TS, Deeks JJ, Dosanjh DP, Guyot-Revol V, Gunatheesan R, Klenerman P, Lalvani A. 2007. Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J Immunol 178: 5217–5226. https://doi.org/10.4049/jimmunol.178.8.5217.
79. Day CL, Abrahams DA, Lerumo L, Janse van Rensburg E, Stone L, O’Rie T, Pienaar B, de Kock M, Kaplan G, Mahomed H, Dheda K, Hanekom WA. 2011. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol 187:2222–2232. https://doi.org/10.4049/jimmunol.1101122.
80. Day CL, Moshi ND, Abrahams DA, van Rooyen M, O’Rie T, de Kock M, Hanekom WA. 2014. Patients with tuberculosis disease have Mycobacterium tuberculosis-specific CD8 T cells with a pro-apoptotic phenotype and impaired proliferative capacity, which is not restored following treatment. PLoS One 9:e94949. https://doi.org/10.1371/journal.pone.0094949.
81. Adekambi T, Ibegbu CC, Cagle S, Kalokhe AS, Wang YF, Hu Y, Day CL, Ray SM, Rengarajan J. 2015. Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response. J Clin Invest 125: 3723. https://doi.org/10.1172/JCI83279.
82. + T cells are functionally and phenotypically different between latent infection and active disease. Eur J Immunol 43:1568–1577. https://doi.org/10.1002/eji.201243262.
83. Lewinsohn DM, Tydeman IS, Frieder M, Grotzke JE, Lines RA, Ahmed S, Prongay KD, Primack SL, Colgin LM, Lewis AD, Lewinsohn DA. 2006. High resolution radiographic and fine immunologic definition of TB disease progression in the rhesus macaque. Microbes Infect 8:2587–2598. https://doi.org/10.1016/j.micinf.2006.07.007.
84. Nyendak MR, Park B, Null MD, Baseke J, Swarbrick G, Mayanja-Kizza H, Nsereko M, Johnson DF, Gitta P, Okwera A, Goldberg S, Bozeman L, Johnson JL, Boom WH, Lewinsohn DA, Lewinsohn DM, Tuberculosis Research Unit and the Tuberculosis Trials Consortium. 2013. Mycobacterium tuberculosis specific CD8(+) T cells rapidly decline with antituberculosis treatment. PLoS One 8:e81564. https://doi.org/10.1371/journal.pone.0081564.
85. + T cells provide an immunologic signature of tuberculosis in young children. Am J Respir Crit Care Med 185: 206–212. https://doi.org/10.1164/rccm.201107-1355OC.
86. Ernst JD. 2012. The immunological life cycle of tuberculosis. Nat Rev Immunol 12:581–591. https://doi.org/10.1038/nri3259.
87. Lindestam Arlehamn CS, Lewinsohn D, Sette A, Lewinsohn D. 2014. Antigens for CD4 and CD8 T cells in tuberculosis. Cold Spring Harb Perspect Med 4:a018465. https://doi.org/10.1101/cshperspect.a018465.
88. Geluk A, van Meijgaarden KE, Joosten SA, Commandeur S, Ottenhoff TH. 2014. Innovative strategies to identify M. tuberculosis antigens and epitopes using genome-wide analyses. Front Immunol 5:256. https://doi.org/10.3389/fimmu.2014.00256.
89. Chegou NN, Essone PN, Loxton AG, Stanley K, Black GF, van der Spuy GD, van Helden PD, Franken KL, Parida SK, Klein MR, Kaufmann SH, Ottenhoff TH, Walzl G. 2012. Potential of host markers produced by infection phase-dependent antigen-stimulated cells for the diagnosis of tuberculosis in a highly endemic area. PLoS One 7:e38501. https://doi.org/10.1371/journal.pone.0038501.
90. Demissie A, Leyten EM, Abebe M, Wassie L, Aseffa A, Abate G, Fletcher H, Owiafe P, Hill PC, Brookes R, Rook G, Zumla A, Arend SM, Klein M, Ottenhoff TH, Andersen P, Doherty TM, VACSEL Study Group. 2006. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol 13:179–186. https://doi.org/10.1128/CVI.13.2.179-186.2006.
91. Moguche AO, Musvosvi M, Penn-Nicholson A, Plumlee CR, Mearns H, Geldenhuys H, Smit E, Abrahams D, Rozot V, Dintwe O, Hoff ST, Kromann I, Ruhwald M, Bang P, Larson RP, Shafiani S, Ma S, Sherman DR, Sette A, Lindestam Arlehamn CS, McKinney DM, Maecker H, Hanekom WA, Hatherill M, Andersen P, Scriba TJ, Urdahl KB. 2017. Antigen availability shapes T cell differentiation and function during tuberculosis. Cell Host Microbe 21:695.e5–706.e5. https://doi.org/10.1016/j.chom.2017.05.012.
92. Shi L, North R, Gennaro ML. 2004. Effect of growth state on transcription levels of genes encoding major secreted antigens of Mycobacterium tuberculosis in the mouse lung. Infect Immun 72:2420–2424. https://doi.org/10.1128/IAI.72.4.2420-2424.2004.
93. Rogerson BJ, Jung YJ, LaCourse R, Ryan L, Enright N, North RJ. 2006. Expression levels of Mycobacterium tuberculosis antigen-encoding genes versus production levels of antigen-specific T cells during stationary level lung infection in mice. Immunology 118:195–201. https://doi.org/10.1111/j.1365-2567.2006.02355.x.
94. Mustafa T, Leversen NA, Sviland L, Wiker HG. 2014. Differential in vivo expression of mycobacterial antigens in Mycobacterium tuberculosis infected lungs and lymph node tissues. BMC Infect Dis 14:535. https://doi.org/10.1186/1471-2334-14-535.
95. Coppola M, van Meijgaarden KE, Franken KL, Commandeur S, Dolganov G, Kramnik I, Schoolnik GK, Comas I, Lund O, Prins C, van den Eeden SJ, Korsvold GE, Oftung F, Geluk A, Ottenhoff TH. 2016. New genome-wide algorithm identifies novel in-vivo expressed Mycobacterium tuberculosis antigens inducing human T-cell responses with classical and unconventional cytokine profiles. Sci Rep 6:37793. https://doi.org/10.1038/srep37793.
96. Godfrey DI, Uldrich AP, McCluskey J, Rossjohn J, Moody DB. 2015. The burgeoning family of unconventional T cells. Nat Immunol 16: 1114–1123. https://doi.org/10.1038/ni.3298.
97. De Libero G, Singhal A, Lepore M, Mori L. 2014. Nonclassical T cells and their antigens in tuberculosis. Cold Spring Harb Perspect Med 4:a018473. https://doi.org/10.1101/cshperspect.a018473.
98. + T-cells recognizing peptides from Mycobacterium tuberculosis (Mtb) presented by HLA-E have an unorthodox Th2-like, multifunctional, Mtb inhibitory phenotype and represent a novel human T-cell subset. PLoS Pathog 11:e1004671. https://doi.org/10.1371/journal.ppat.1004671.
99. + T cells. J Exp Med 196:1473–1481. https://doi.org/10.1084/jem.20020609.
100. Joosten SA, van Meijgaarden KE, van Weeren PC, Kazi F, Geluk A, Savage ND, Drijfhout JW, Flower DR, Hanekom WA, Klein MR, Ottenhoff TH. 2010. Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. PLoS Pathog 6:e1000782. https://doi.org/10.1371/journal.ppat.1000782.
101. Caccamo N, Pietra G, Sullivan LC, Brooks AG, Prezzemolo T, La Manna MP, Di Liberto D, Joosten SA, van Meijgaarden KE, Di Carlo P, Titone L, Moretta L, Mingari MC, Ottenhoff TH, Dieli F. 2015. Human CD8 T lymphocytes recognize Mycobacterium tuberculosis antigens presented by HLA-E during active tuberculosis and express type 2 cytokines. Eur J Immunol 45:1069–1081. https://doi.org/10.1002/eji.201445193.
102. Gilleron M, Stenger S, Mazorra Z, Wittke F, Mariotti S, Bohmer G, Prandi J, Mori L, Puzo G, De Libero G. 2004. Diacylated sulfoglycolipids are novel mycobacterial antigens stimulating CD1-restricted T cells during infection with Mycobacterium tuberculosis. J Exp Med 199:649–659. https://doi.org/10.1084/jem.20031097.
103. Moody DB, Ulrichs T, Muhlecker W, Young DC, Gurcha SS, Grant E, Rosat JP, Brenner MB, Costello CE, Besra GS, Porcelli SA. 2000. CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature 404:884–888. https://doi.org/10.1038/35009119.
104. Kwon YS, Cho YN, Kim MJ, Jin HM, Jung HJ, Kang JH, Park KJ, Kim TJ, Kee HJ, Kim N, Kee SJ, Park YW. 2015. Mucosal-associated invariant T cells are numerically and functionally deficient in patients with mycobacterial infection and reflect disease activity. Tuberculosis (Edinb) 95:267–274. https://doi.org/10.1016/j.tube.2015.03.004.
105. Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, Delepine J, Winata E, Swarbrick GM, Chua W-J, Yu YYL, Lantz O, Cook MS, Null MD, Jacoby DB, Harriff MJ, Lewinsohn DA, Hansen TH, Lewinsohn DM. 2010. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol 8:e1000407. https://doi.org/10.1371/journal.pbio.1000407.
106. Le Bourhis L, Martin E, Peguillet I, Guihot A, Froux N, Core M, Levy E, Dusseaux M, Meyssonnier V, Premel V, Ngo C, Riteau B, Duban L, Robert D, Huang S, Rottman M, Soudais C, Lantz O. 2010. Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol 11:701–708. https://doi.org/10.1038/ni.1890.
107. Snyder-Cappione JE, Nixon DF, Loo CP, Chapman JM, Meiklejohn DA, Melo FF, Costa PR, Sandberg JK, Rodrigues DS, Kallas EG. 2007. Individuals with pulmonary tuberculosis have lower levels of circulating CD1d-restricted NKT cells. J Infect Dis 195:1361–1364. https://doi.org/10.1086/513567.
108. Sutherland JS, Hill PC, Adetifa IM, de Jong BC, Donkor S, Joosten SA, Opmeer L, Haks MC, Ottenhoff TH, Adegbola RA, Ota MO. 2011. Identification of probable early-onset biomarkers for tuberculosis disease progression. PLoS One 6:e25230. https://doi.org/10.1371/journal.pone.0025230.
109. Sigal GB, Segal MR, Mathew A, Jarlsberg L, Wang M, Barbero S, Small N, Haynesworth K, Davis JL, Weiner M, Whitworth WC, Jacobs J, Schorey J, Lewinsohn DM, Nahid P. 2017. Biomarkers of tuberculosis severity and treatment effect: a directed screen of 70 host markers in a randomized clinical trial. EBioMedicine 25:112–121. https://doi.org/10.1016/j.ebiom.2017.10.018.
110. Bark CM, Manceur AM, Malone LL, Nsereko M, Okware B, Mayanja HK, Joloba ML, Rajotte I, Mentinova M, Kay P, Lo S, Tremblay P, Stein CM, Boom WH, Paramithiotis E. 2017. Identification of host proteins predictive of early stage Mycobacterium tuberculosis infection. EBioMedicine 21:150–157. https://doi.org/10.1016/j.ebiom.2017.06.019.
111. De Groote MA, Nahid P, Jarlsberg L, Johnson JL, Weiner M, Muzanyi G, Janjic N, Sterling DG, Ochsner UA. 2013. Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PLoS One 8:e61002. https://doi.org/10.1371/journal.pone.0061002.
112. Esterhuyse MM, Weiner J, III, Caron E, Loxton AG, Iannaccone M, Wagman C, Saikali P, Stanley K, Wolski WE, Mollenkopf HJ, Schick M, Aebersold R, Linhart H, Walzl G, Kaufmann SH. 2015. Epigenetics and proteomics join transcriptomics in the quest for tuberculosis biomarkers. mBio 6:e01187-15. https://doi.org/10.1128/mBio.01187-15.
113. Weiner J, III, Parida SK, Maertzdorf J, Black GF, Repsilber D, Telaar A, Mohney RP, Arndt-Sullivan C, Ganoza CA, Fae KC, Walzl G, Kaufmann SH. 2012. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS One 7:e40221. https://doi.org/10.1371/journal.pone.0040221.
114. Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Hussey GD, Abrahams D, Kafaar F, Hawkridge T, Verver S, Hughes EJ, Ota M, Sutherland J, Howe R, Dockrell HM, Boom WH, Thiel B, Ottenhoff THM, Mayanja-Kizza H, Crampin AC, Downing K, Hatherill M, Valvo J, Shankar S, Parida SK, Kaufmann SHE, Walzl G, Aderem A, Hanekom WA. 2016. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 387:2312–2322. https://doi.org/10.1016/S0140-6736(15) 01316-1.
115. Onozaki I, Law I, Sismanidis C, Zignol M, Glaziou P, Floyd K. 2015. National tuberculosis prevalence surveys in Asia, 1990-2012: an overview of results and lessons learned. Trop Med Int Health 20:1128–1145. https://doi.org/10.1111/tmi.12534.
116. Mao TE, Okada K, Yamada N, Peou S, Ota M, Saint S, Kouet P, Chea M, Keo S, Pheng SH, Tieng S, Khun KE, Sugamoto T, Matsumoto H, Yoshiyama T, Ito K, Onozaki I. 2014. Cross-sectional studies of tuberculosis prevalence in Cambodia between 2002 and 2011. Bull World Health Organ 92:573–581. https://doi.org/10.2471/BLT.13.131581.
117. Guwatudde D, Nakakeeto M, Jones-Lopez EC, Maganda A, Chiunda A, Mugerwa RD, Ellner JJ, Bukenya G, Whalen CC. 2003. Tuberculosis in household contacts of infectious cases in Kampala, Uganda. Am J Epidemiol 158:887–898. https://doi.org/10.1093/aje/kwg227.
118. van’t Hoog AH, Laserson KF, Githui WA, Meme HK, Agaya JA, Odeny LO, Muchiri BG, Marston BJ, DeCock KM, Borgdorff MW. 2011. High prevalence of pulmonary tuberculosis and inadequate case finding in rural western Kenya. Am J Respir Crit Care Med 183:1245–1253. https://doi.org/10.1164/rccm.201008-1269OC.
119. Oni T, Burke R, Tsekela R, Bangani N, Seldon R, Gideon HP, Wood K, Wilkinson KA, Ottenhoff TH, Wilkinson RJ. 2011. High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening. Thorax 66:669–673. https://doi.org/10.1136/thx.2011.160168.
120. Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, Vogt M, Bekker LG, Wood R. 2011. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 8:e1001067. https://doi.org/10.1371/journal.pmed.1001067.
121. Lawn SD, Kerkhoff AD, Wood R. 2011. Progression of subclinical culture-positive tuberculosis to symptomatic disease in HIV-infected individuals. AIDS 25:2190–2191. https://doi.org/10.1097/QAD.0b013e32834cda4e.
122. Corbett EL, Bandason T, Cheung YB, Munyati S, Godfrey-Faussett P, Hayes R, Churchyard G, Butterworth A, Mason P. 2007. Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med 4:e22. https://doi.org/10.1371/journal.pmed.0040022.
123. Mtei L, Matee M, Herfort O, Bakari M, Horsburgh CR, Waddell R, Cole BF, Vuola JM, Tvaroha S, Kreiswirth B, Pallangyo K, von Reyn CF. 2005. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 40:1500–1507. https://doi.org/10.1086/429825.
124. Lewis JJ, Charalambous S, Day JH, Fielding KL, Grant AD, Hayes RJ, Corbett EL, Churchyard GJ. 2009. HIV infection does not affect active case finding of tuberculosis in South African gold miners. Am J Respir Crit Care Med 180:1271–1278. https://doi.org/10.1164/rccm.200806-846OC.
125. Swindells S, Komarow L, Tripathy S, Cain KP, MacGregor RR, Achkar JM, Gupta A, Veloso VG, Asmelash A, Omoz-Oarhe AE, Gengiah S, Lalloo U, Allen R, Shiboski C, Andersen J, Qasba SS, Katzenstein DK. 2013. Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group protocol A5253. Int J Tuberc Lung Dis 17:532–539. https://doi.org/10.5588/ijtld.12.0737.
126. Swaminathan S, Paramasivan CN, Kumar SR, Mohan V, Venkatesan P. 2004. Unrecognised tuberculosis in HIV-infected patients: sputum culture is a useful tool. Int J Tuberc Lung Dis 8:896–898.
127. Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, Bearnot B, Allen J, Walensky RP, Freedberg KA. 2010. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 51:823–829. https://doi.org/10.1086/656282.
128. Henostroza G, Harris JB, Chitambi R, Siyambango M, Turnbull ER, Maggard KR, Kruuner A, Kapata N, Reid SE. 2016. High prevalence of tuberculosis in newly enrolled HIV patients in Zambia: need for enhanced screening approach. Int J Tuberc Lung Dis 20:1033–1039. https://doi.org/10.5588/ijtld.15.0651.
129. Kimerling ME, Schuchter J, Chanthol E, Kunthy T, Stuer F, Glaziou P, Ee O. 2002. Prevalence of pulmonary tuberculosis among HIV-infected persons in a home care program in Phnom Penh, Cambodia. Int J Tuberc Lung Dis 6:988–994.
130. Kufa T, Mngomezulu V, Charalambous S, Hanifa Y, Fielding K, Grant AD, Wada N, Chaisson RE, Churchyard GJ, Gounder CR. 2012. Undiagnosed tuberculosis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control. J Acquir Immune Defic Syndr 60: e22–e28. https://doi.org/10.1097/QAI.0b013e318251ae0b.
131. Shah S, Demissie M, Lambert L, Ahmed J, Leulseged S, Kebede T, Melaku Z, Mengistu Y, Lemma E, Wells CD, Wuhib T, Nelson LJ. 2009. Intensified tuberculosis case finding among HIV-infected persons from a voluntary counseling and testing center in Addis Ababa, Ethiopia. J Acquir Immune Defic Syndr 50:537–545. https://doi.org/10.1097/QAI.0b013e318196761c.
132. Chheng P, Tamhane A, Natpratan C, Tan V, Lay V, Sar B, Kimerling ME. 2008. Pulmonary tuberculosis among patients visiting a voluntary confidential counseling and testing center, Cambodia. Int J Tuberc Lung Dis 12:54–62.
133. Wood R, Middelkoop K, Myer L, Grant AD, Whitelaw A, Lawn SD, Kaplan G, Huebner R, McIntyre J, Bekker LG. 2007. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 175:87–93. https://doi.org/10.1164/rccm.200606-759OC.
134. Day JH, Charalambous S, Fielding KL, Hayes RJ, Churchyard GJ, Grant AD. 2006. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis 10:523–529.
135. Kancheya N, Luhanga D, Harris JB, Morse J, Kapata N, Bweupe M, Henostroza G, Reid SE. 2014. Integrating active tuberculosis case finding in antenatal services in Zambia. Int J Tuberc Lung Dis 18: 1466–1472. https://doi.org/10.5588/ijtld.14.0920.
136. LaCourse SM, Cranmer LM, Matemo D, Kinuthia J, Richardson BA, John-Stewart G, Horne DJ. 2016. Tuberculosis case finding in HIV-infected pregnant women in Kenya reveals poor performance of symptom screening and rapid diagnostic tests. J Acquir Immune Defic Syndr 71:219–227. https://doi.org/10.1097/QAI.0000000000000826.
137. Telisinghe L, Fielding KL, Malden JL, Hanifa Y, Churchyard GJ, Grant AD, Charalambous S. 2014. High tuberculosis prevalence in a South African prison: the need for routine tuberculosis screening. PLoS One 9:e87262. https://doi.org/10.1371/journal.pone.0087262.
138. Agizew TB, Arwady MA, Yoon JC, Nyirenda S, Mosimaneotsile B, Tedla Z, Motsamai O, Kilmarx PH, Wells CD, Samandari T. 2010. Tuberculosis in asymptomatic HIV-infected adults with abnormal chest radiographs screened for tuberculosis prevention. Int J Tuberc Lung Dis 14:45–51.
139. Bates M, O’Grady J, Mwaba P, Chilukutu L, Mzyece J, Cheelo B, Chilufya M, Mukonda L, Mumba M, Tembo J, Chomba M, Kapata N, Rachow A, Clowes P, Maeurer M, Hoelscher M, Zumla A. 2012. Evaluation of the burden of unsuspected pulmonary tuberculosis and comorbidity with non-communicable diseases in sputum producing adult inpatients. PLoS One 7:e40774. https://doi.org/10.1371/journal.pone.0040774.
140. Cohen T, Murray M, Wallengren K, Alvarez GG, Samuel EY, Wilson D. 2010. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med 7:e1000296. https://doi.org/10.1371/journal.pmed.1000296.
141. World Health Organization. 2017. Global tuberculosis report. World Health Organization, Geneva, Switzerland.
142. Hoa NB, Sy DN, Nhung NV, Tiemersma EW, Borgdorff MW, Cobelens FG. 2010. National survey of tuberculosis prevalence in Viet Nam. Bull World Health Organ 88:273–280. https://doi.org/10.2471/BLT.09.067801.
143. National Tuberculosis Control Program. 2012. Report: second national tuberculosis prevalence survey Cambodia, 2011. Ministry of Health, Phnom Penh, Cambodia.
144. Hong YP, Kim SJ, Lew WJ, Lee EK, Han YC. 1998. The seventh nationwide tuberculosis prevalence survey in Korea, 1995. Int J Tuberc Lung Dis 2:27–36.
145. Wang L, Zhang H, Ruan Y, Chin DP, Xia Y, Cheng S, Chen M, Zhao Y, Jiang S, Du X, He G, Li J, Wang S, Chen W, Xu C, Huang F, Liu X, Wang Y. 2014. Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data. Lancet 383:2057–2064. https://doi.org/10.1016/S0140-6736(13)62639-2.
146. Cain KP, McCarthy KD, Heilig CM, Monkongdee P, Tasaneeyapan T, Kanara N, Kimerling ME, Chheng P, Thai S, Sar B, Phanuphak P, Teeratakulpisarn N, Phanuphak N, Nguyen HD, Hoang TQ, Le HT, Varma JK. 2010. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 362:707–716. https://doi.org/10.1056/NEJMoa0907488.
147. Ahmad Khan F, Verkuijl S, Parrish A, Chikwava F, Ntumy R, El-Sadr W, Howard AA. 2014. Performance of symptom-based tuberculosis screen-ing among people living with HIV: not as great as hoped. AIDS 28: 1463–1472. https://doi.org/10.1097/QAD.0000000000000278.
148. Modi S, Cavanaugh JS, Shiraishi RW, Alexander HL, McCarthy KD, Burmen B, Muttai H, Heilig CM, Nakashima AK, Cain KP. 2016. Performance of clinical screening algorithms for tuberculosis intensified case finding among people living with HIV in Western Kenya. PLoS One 11:e0167685. https://doi.org/10.1371/journal.pone.0167685.
149. Rangaka MX, Wilkinson RJ, Glynn JR, Boulle A, van Cutsem G, Goliath R, Mathee S, Maartens G. 2012. Effect of antiretroviral therapy on the diagnostic accuracy of symptom screening for intensified tuberculosis case finding in a South African HIV clinic. Clin Infect Dis 55:1698–1706. https://doi.org/10.1093/cid/cis775.
150. Ayles H, Schaap A, Nota A, Sismanidis C, Tembwe R, De Haas P, Muyoyeta M, Beyers N. 2009. Prevalence of tuberculosis, HIV and respiratory symptoms in two Zambian communities: implications for tuberculosis control in the era of HIV. PLoS One 4:e5602. https://doi.org/10.1371/journal.pone.0005602.
151. Corbett EL, Zezai A, Cheung YB, Bandason T, Dauya E, Munyati SS, Butterworth AE, Rusikaniko S, Churchyard GJ, Mungofa S, Hayes RJ, Mason PR. 2010. Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status. Bull World Health Organ 88:13–21. https://doi.org/10.2471/BLT.08.055467.
152. Corbett EL, Bandason T, Cheung YB, Makamure B, Dauya E, Munyati SS, Churchyard GJ, Williams BG, Butterworth AE, Mungofa S, Hayes RJ, Mason PR. 2009. Prevalent infectious tuberculosis in Harare, Zimbabwe: burden, risk factors and implications for control. Int J Tuberc Lung Dis 13:1231–1237.
153. Kerkhoff AD, Wood R, Lowe DM, Vogt M, Lawn SD. 2013. Blood neutrophil counts in HIV-infected patients with pulmonary tuberculosis: association with sputum mycobacterial load. PLoS One 8:e67956. https://doi.org/10.1371/journal.pone.0067956.
154. Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, Wood R. 2010. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 24:1323–1328.
155. Hoffmann CJ, Variava E, Rakgokong M, Masonoke K, van der Watt M, Chaisson RE, Martinson NA. 2013. High prevalence of pulmonary tuberculosis but low sensitivity of symptom screening among HIV-infected pregnant women in South Africa. PLoS One 8:e62211. https://doi.org/10.1371/journal.pone.0062211.
156. Ai JW, Ruan QL, Liu QH, Zhang WH. 2016. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect 5:e10. https://doi.org/10.1038/emi.2016.10.
157. Flynn JL, Chan J. 2001. Tuberculosis: latency and reactivation. Infect Immun 69:4195–4201. https://doi.org/10.1128/IAI.69.7.4195-4201.2001.
158. Comstock GW. 1982. Epidemiology of tuberculosis. Am Rev Respir Dis 125:8–15.
159. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. 2011. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One 6:e17601. https://doi.org/10.1371/journal.pone.0017601.
160. Bates M, Mudenda V, Shibemba A, Kaluwaji J, Tembo J, Kabwe M, Chimoga C, Chilukutu L, Chilufya M, Kapata N, Hoelscher M, Maeurer M, Mwaba P, Zumla A. 2015. Burden of tuberculosis at post mortem in inpatients at a tertiary referral centre in sub-Saharan Africa: a prospective descriptive autopsy study. Lancet Infect Dis 15:544–551. https://doi.org/10.1016/S1473-3099(15)70058-7.
161. Gupta RK, Lucas SB, Fielding KL, Lawn SD. 2015. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS 29:1987–2002. https://doi.org/10.1097/QAD.0000000000000802.
162. Calligaro GL, Zijenah LS, Peter JG, Theron G, Buser V, McNerney R, Bara W, Bandason T, Govender U, Tomasicchio M, Smith L, Mayosi BM, Dheda K. 2017. Effect of new tuberculosis diagnostic technologies on community-based intensified case finding: a multicentre randomised controlled trial. Lancet Infect Dis 17:441–450. https://doi.org/10.1016/S1473-3099(16)30384-X.
163. Dowdy DW, Basu S, Andrews JR. 2013. Is passive diagnosis enough? The impact of subclinical disease on diagnostic strategies for tuberculosis. Am J Respir Crit Care Med 187:543–551. https://doi.org/10.1164/rccm.201207-1217OC.
164. Reid A, Grant AD, White RG, Dye C, Vynnycky E, Fielding K, Churchyard G, Pillay Y. 2015. Accelerating progress towards tuberculosis elimination: the need for combination treatment and prevention. Int J Tuberc Lung Dis 19:5–9. https://doi.org/10.5588/ijtld.14.0078.
165. Houben R, Menzies NA, Sumner T, Huynh GH, Arinaminpathy N, Goldhaber-Fiebert JD, Lin HH, Wu CY, Mandal S, Pandey S, Suen SC, Bendavid E, Azman AS, Dowdy DW, Bacaer N, Rhines AS, Feldman MW, Handel A, Whalen CC, Chang ST, Wagner BG, Eckhoff PA, Trauer JM, Denholm JT, McBryde ES, Cohen T, Salomon JA, Pretorius C, Lalli M, Eaton JW, Boccia D, Hosseini M, Gomez GB, Sahu S, Daniels C, Ditiu L, Chin DP, Wang L, Chadha VK, Rade K, Dewan P, Hippner P, Charalambous S, Grant AD, Churchyard G, Pillay Y, Mametja LD, Kimerling ME, Vassall A, White RG. 2016. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. Lancet Glob Health 4:e806–e815. https://doi.org/10.1016/S2214-109X(16)30199-1.
166. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, Falzon D, Floyd K, Gargioni G, Getahun H, Gilpin C, Glaziou P, Grzemska M, Mirzayev F, Nakatani H, Raviglione M. 2015. WHO’s new end TB strategy. Lancet 385:1799–1801. https://doi.org/10.1016/S0140-6736(15) 60570-0.
167. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM. 2002. A meta-analysis of the effect of bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 57:804–809. https://doi.org/10.1136/thorax.57.9.804.
168. Farhat M, Greenaway C, Pai M, Menzies D. 2006. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 10:1192–1204.
169. Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, Metcalfe JZ, Cattamanchi A, Dowdy DW, Dheda K, Banaei N. 2014. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 27:3–20. https://doi.org/10.1128/CMR.00034-13.
170. Tagmouti S, Slater M, Benedetti A, Kik SV, Banaei N, Cattamanchi A, Metcalfe J, Dowdy D, van Zyl Smit R, Dendukuri N, Pai M, Denkinger C. 2014. Reproducibility of interferon gamma (IFN-gamma) release assays. A systematic review. Ann Am Thorac Soc 11:1267–1276. https://doi.org/10.1513/AnnalsATS.201405-188OC.
171. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, Fielding K, Wilkinson RJ, Pai M. 2012. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 12:45–55. https://doi.org/10.1016/S1473-3099(11)70210-9.
172. Diel R, Loddenkemper R, Nienhaus A. 2012. Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 142:63–75. https://doi.org/10.1378/chest.11-3157.
173. Dye C. 2011. Practical preventive therapy for tuberculosis? N Engl J Med 365:2230–2231. https://doi.org/10.1056/NEJMe1111859.
174. Kasprowicz VO, Churchyard G, Lawn SD, Squire SB, Lalvani A. 2011. Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas. J Infect Dis 204(Suppl 4):S1168–S1178. https://doi.org/10.1093/infdis/jir449.
175. Robertson BD, Altmann D, Barry C, Bishai B, Cole S, Dick T, Duncan K, Dye C, Ehrt S, Esmail H, Flynn J, Hafner R, Handley G, Hanekom W, van Helden P, Kaplan G, Kaufmann SH, Kim P, Lienhardt C, Mizrahi V, Rubin E, Schnappinger D, Sherman D, Thole J, Vandal O, Walzl G, Warner D, Wilkinson R, Young D. 2012. Detection and treatment of subclinical tuberculosis. Tuberculosis (Edinb) 92:447–452. https://doi.org/10.1016/j.tube.2012.06.004.
176. Esmail H, Barry CE, III, Young DB, Wilkinson RJ. 2014. The ongoing challenge of latent tuberculosis. Philos Trans R Soc Lond B Biol Sci 369:20130437. https://doi.org/10.1098/rstb.2013.0437.
177. Hoff ST, Peter JG, Theron G, Pascoe M, Tingskov PN, Aggerbeck H, Kolbus D, Ruhwald M, Andersen P, Dheda K. 2016. Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection. Eur Respir J 47:919–928. https://doi.org/10.1183/13993003.01464-2015.
178. Barcellini L, Borroni E, Brown J, Brunetti E, Codecasa L, Cugnata F, Dal Monte P, Di Serio C, Goletti D, Lombardi G, Lipman M, Rancoita PM, Tadolini M, Cirillo DM. 2016. First independent evaluation of QuantiFERON-TB Plus performance. Eur Respir J 47:1587–1590. https://doi.org/10.1183/13993003.02033-2015.
179. Li F, Xu M, Qin C, Xia L, Xiong Y, Xi X, Fan X, Gu J, Pu J, Wu Q, Lu S, Wang G. 2016. Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial. Clin Microbiol Infect 22:889.e9–889.e16. https://doi.org/10.1016/j.cmi.2016.07.015.
180. Ruhwald M, Aggerbeck H, Gallardo RV, Hoff ST, Villate JI, Borregaard B, Martinez JA, Kromann I, Penas A, Anibarro LL, de Souza-Galvao ML, Sanchez F, Rodrigo-Pendas JA, Noguera-Julian A, Martinez-Lacasa X, Tunez MV, Fernandez VL, Millet JP, Moreno A, Cobos N, Miro JM, Roldan L, Orcau A, Andersen P, Cayla JA. 2017. Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon gamma release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial. Lancet Respir Med 5:259–268. https://doi.org/10.1016/S2213-2600(16)30436-2.
181. Aksenova V. 2011. DIASKINTEST as a screening metod [sic] at the mass child health examination for tuberculosis in Russia. Eur Respir J 38:295.
182. Yi L, Sasaki Y, Nagai H, Ishikawa S, Takamori M, Sakashita K, Saito T, Fukushima K, Igarashi Y, Aono A, Chikamatsu K, Yamada H, Takaki A, Mori T, Mitarai S. 2016. Evaluation of QuantiFERON-TB Gold Plus for detection of Mycobacterium tuberculosis infection in Japan. Sci Rep 6:30617. https://doi.org/10.1038/srep30617.
183. Hoffmann H, Avsar K, Gores R, Mavi SC, Hofmann-Thiel S. 2016. Equal sensitivity of the new generation QuantiFERON-TB Gold plus in direct comparison with the previous test version QuantiFERON-TB Gold IT. Clin Microbiol Infect 22:701–703. https://doi.org/10.1016/j.cmi.2016.05.006.
184. Nikolova M, Markova R, Drenska R, Muhtarova M, Todorova Y, Dimitrov V, Taskov H, Saltini C, Amicosante M. 2013. Antigen-specific CD4-and CD8-positive signatures in different phases of Mycobacterium tuberculosis infection. Diagn Microbiol Infect Dis 75:277–281. https://doi.org/10.1016/j.diagmicrobio.2012.11.023.
185. World Health Organization. 2017. Consensus meeting report: development of a target product profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease. World Health Organization, Geneva, Switzerland.
186. Jacobsen M, Repsilber D, Gutschmidt A, Neher A, Feldmann K, Mollenkopf HJ, Ziegler A, Kaufmann SH. 2007. Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med (Berl) 85:613–621. https://doi.org/10.1007/s00109-007-0157-6.
187. Cliff JM, Lee JS, Constantinou N, Cho JE, Clark TG, Ronacher K, King EC, Lukey PT, Duncan K, Van Helden PD, Walzl G, Dockrell HM. 2013. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis 207:18–29. https://doi.org/10.1093/infdis/jis499.
188. Maertzdorf J, Repsilber D, Parida SK, Stanley K, Roberts T, Black G, Walzl G, Kaufmann SH. 2011. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun 12:15–22. https://doi.org/10.1038/gene.2010.51.
189. Ottenhoff TH, Verreck FA, Hoeve MA, van de Vosse E, Ottenhoff THM, Verreck FAW, Hoeve MA, van de Vosse E. 2005. Control of human host immunity to mycobacteria. Tuberculosis 85:53–64. https://doi.org/10.1016/j.tube.2004.09.011. (Erratum, 86:74–75, 2006.)
190. Petruccioli E, Chiacchio T, Pepponi I, Vanini V, Urso R, Cuzzi G, Barcellini L, Cirillo DM, Palmieri F, Ippolito G, Goletti D. 2016. First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus. J Infect 73:588–597. https://doi.org/10.1016/j.jinf.2016.09.008.
191. Fiore-Gartland A, Carpp L, Naidoo K, Thompson E, Zak D, Self S, Churchyard G, Walzl G, Penn-Nicholson A, Scriba T, Hatherill M. 2018. Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. Tuberculosis (Edinb) 109:61–68. https://doi.org/10.1016/j.tube.2017.11.009.
192. Manabe YC, Breen R, Perti T, Girardi E, Sterling TR. 2009. Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis 199:437–444. https://doi.org/10.1086/595985.
193. Sohn H, Aero AD, Menzies D, Behr M, Schwartzman K, Alvarez GG, Dan A, McIntosh F, Pai M, Denkinger CM. 2014. Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact. Clin Infect Dis 58:970–976. https://doi.org/10.1093/cid/ciu022.
194. World Health Organization. 2014. High-priority target product profiles for new tuberculosis diagnostics. World Health Organization, Geneva, Switzerland.
195. Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, Urbanczik R, Perkins M, Aziz MA, Pai M. 2006. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 6:570–581. https://doi.org/10.1016/S1473-3099(06)70578-3.
196. Parsons LM, Somoskovi A, Gutierrez C, Lee E, Paramasivan CN, Abimiku A, Spector S, Roscigno G, Nkengasong J. 2011. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev 24:314–350. https://doi.org/10.1128/CMR.00059-10.
197. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O’Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363:1005–1015. https://doi.org/10.1056/NEJMoa0907847.
198. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L, Caceres T, Mehdiyev R, Raymond L, Whitelaw A, Sagadevan K, Alexander H, Albert H, Cobelens F, Cox H, Alland D, Perkins MD. 2011. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377:1495–1505. https://doi.org/10.1016/S0140-6736(11)60438-8.
199. Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, Hall SL, Chakravorty S, Cirillo DM, Tukvadze N, Bablishvili N, Stevens W, Scott L, Rodrigues C, Kazi MI, Joloba M, Nakiyingi L, Nicol MP, Ghe-brekristos Y, Anyango I, Murithi W, Dietze R, Lyrio Peres R, Skrahina A, Auchynka V, Chopra KK, Hanif M, Liu X, Yuan X, Boehme CC, Ellner JJ, Denkinger CM. 2018. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis 18:76–84. https://doi.org/10.1016/S1473-3099(17)30691-6.
200. Wood RC, Luabeya AK, Weigel KM, Wilbur AK, Jones-Engel L, Hatherill M, Cangelosi GA. 2015. Detection of Mycobacterium tuberculosis DNA on the oral mucosa of tuberculosis patients. Sci Rep 5:8668. https://doi.org/10.1038/srep08668.
201. LaCourse SM, Pavlinac PB, Cranmer LM, Njuguna IN, Mugo C, Gatimu J, Stern J, Walson JL, Maleche-Obimbo E, Oyugi J, Wamalwa D, John-Stewart G. 2018. Stool Xpert MTB/RIF and urine lipoarabinomannan for the diagnosis of tuberculosis in hospitalized HIV-infected children. AIDS 32:69–78. https://doi.org/10.1097/QAD.0000000000001662.
202. Young BL, Mlamla Z, Gqamana PP, Smit S, Roberts T, Peter J, Theron G, Govender U, Dheda K, Blackburn J. 2014. The identification of tuberculosis biomarkers in human urine samples. Eur Respir J 43:1719–1729. https://doi.org/10.1183/09031936.00175113.
203. Shah M, Hanrahan C, Wang ZY, Dendukuri N, Lawn SD, Denkinger CM, Steingart KR. 2016. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults. Cochrane Database Syst Rev 2016:Cd011420. https://doi.org/10.1002/14651858.CD011420.pub2.
204. World Health Organization. 2015. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. World Health Organization, Geneva, Switzerland.
205. Bajema K, Losina E, Coleman S, Giddy J, Ross D, Freedberg K, Bassett I, Drain P. 2017. Subclinical tuberculosis among HIV positive adults in South Africa: a cohort study, abstr SOA-395-13. 48th Union World Conf Lung Health, Guadalajara, Mexico, 11 to 14 October 2017. http://www.abstractserver.com/TheUnion2017/TheUnion2017_Abstracts_ Web.pdf.
206. Crawford AC, Laurentius LB, Mulvihill TS, Granger JH, Spencer JS, Chatterjee D, Hanson KE, Porter MD. 2016. Detection of the tuberculosis antigenic marker mannose-capped lipoarabinomannan in pre-treated serum by surface-enhanced Raman scattering. Analyst 142: 186–196. https://doi.org/10.1039/C6AN02110G.
207. Hamasur B, Bruchfeld J, van Helden P, Kallenius G, Svenson S. 2015. A sensitive urinary lipoarabinomannan test for tuberculosis. PLoS One 10:e0123457. https://doi.org/10.1371/journal.pone.0123457.
208. Laurentius LB, Crawford AC, Mulvihill TS, Granger JH, Robinson R, Spencer JS, Chatterjee D, Hanson KE, Porter MD. 2016. Importance of specimen pretreatment for the low-level detection of mycobacterial lipoarabinomannan in human serum. Analyst 142:177–185. https://doi.org/10.1039/C6AN02109C.
209. Liu C, Zhao Z, Fan J, Lyon CJ, Wu HJ, Nedelkov D, Zelazny AM, Olivier KN, Cazares LH, Holland SM, Graviss EA, Hu Y. 2017. Quantification of circulating Mycobacterium tuberculosis antigen peptides allows rapid diagnosis of active disease and treatment monitoring. Proc Natl Acad Sci U S A 114:3969–3974. https://doi.org/10.1073/pnas.1621360114.
210. Ko ER, Yang WE, McClain MT, Woods CW, Ginsburg GS, Tsalik EL. 2015. What was old is new again: using the host response to diagnose infectious disease. Expert Rev Mol Diagn 15:1143–1158. https://doi.org/10.1586/14737159.2015.1059278.
211. Holcomb ZE, Tsalik EL, Woods CW, McClain MT. 2017. Host-based peripheral blood gene expression analysis for diagnosis of infectious diseases. J Clin Microbiol 55:360–368. https://doi.org/10.1128/JCM.01057-16.
212. Walzl G, Haks MC, Joosten SA, Kleynhans L, Ronacher K, Ottenhoff TH. 2014. Clinical immunology and multiplex biomarkers of human tuberculosis. Cold Spring Harb Perspect Med 5:a018515. https://doi.org/10.1101/cshperspect.a018515.
213. Haas CT, Roe JK, Pollara G, Mehta M, Noursadeghi M. 2016. Diagnostic ‘omics’ for active tuberculosis. BMC Med 14:37. https://doi.org/10.1186/s12916-016-0583-9.
214. Bloom CI, Graham CM, Berry MP, Wilkinson KA, Oni T, Rozakeas F, Xu Z, Rossello-Urgell J, Chaussabel D, Banchereau J, Pascual V, Lipman M, Wilkinson RJ, O’Garra A. 2012. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS One 7:e46191. https://doi.org/10.1371/journal.pone.0046191.
215. Latorre I, Leidinger P, Backes C, Dominguez J, de Souza-Galvao ML, Maldonado J, Prat C, Ruiz-Manzano J, Sanchez F, Casas I, Keller A, von Briesen H, Knobel H, Meese E, Meyerhans A. 2015. A novel whole-blood miRNA signature for a rapid diagnosis of pulmonary tuberculosis. Eur Respir J 45:1173–1176. https://doi.org/10.1183/09031936.00221514.
216. Kaforou M, Wright VJ, Levin M. 2014. Host RNA signatures for diagnostics: an example from paediatric tuberculosis in Africa. J Infect 69(Suppl 1):S28–S31. https://doi.org/10.1016/j.jinf.2014.08.006.
217. Satproedprai N, Wichukchinda N, Suphankong S, Inunchot W, Kuntima T, Kumpeerasart S, Wattanapokayakit S, Nedsuwan S, Yanai H, Higuchi K, Harada N, Mahasirimongkol S. 2015. Diagnostic value of blood gene expression signatures in active tuberculosis in Thais: a pilot study. Genes Immun 16:253–260. https://doi.org/10.1038/gene.2015.4.
218. Sweeney TE, Braviak L, Tato CM, Khatri P. 2016. Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis. Lancet Respir Med 4:213–224. https://doi.org/10.1016/S2213-2600(16) 00048-5.
219. Petruccioli E, Scriba TJ, Petrone L, Hatherill M, Cirillo DM, Joosten SA, Ottenhoff TH, Denkinger CM, Goletti D. 2016. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur Respir J 48:1751–1763. https://doi.org/10.1183/13993003.01012-2016.
220. Djoba Siawaya JF, Ruhwald M, Eugen-Olsen J, Walzl G. 2007. Correlates for disease progression and prognosis during concurrent HIV/TB infection. Int J Infect Dis 11:289–299. https://doi.org/10.1016/j.ijid.2007.02.001.
221. Gliddon HD, Herberg JA, Levin M, Kaforou M. 2018. Genome-wide host RNA signatures of infectious diseases: discovery and clinical translation. Immunology 153:171–178. https://doi.org/10.1111/imm.12841.
222. Gibson G. 2008. The environmental contribution to gene expression profiles. Nat Rev Genet 9:575–581. https://doi.org/10.1038/nrg2383.
223. Joosten SA, Fletcher HA, Ottenhoff TH. 2013. A helicopter perspective on TB biomarkers: pathway and process based analysis of gene expression data provides new insight into TB pathogenesis. PLoS One 8:e73230. https://doi.org/10.1371/journal.pone.0073230.
224. Sandgren A, Vonk Noordegraaf-Schouten M, van Kessel F, Stuurman A, Oordt-Speets A, van der Werf MJ. 2016. Initiation and completion rates for latent tuberculosis infection treatment: a systematic review. BMC Infect Dis 16:204. https://doi.org/10.1186/s12879-016-1550-y.
225. Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. 2016. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis 16:1269–1278. https://doi.org/10.1016/S1473-3099(16)30216-X.
226. Dheda K, Chang KC, Guglielmetti L, Furin J, Schaaf HS, Chesov D, Esmail A, Lange C. 2017. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Microbiol Infect 23:131–140. https://doi.org/10.1016/j.cmi.2016.10.008.
227. Dheda K, Gumbo T, Gandhi NR, Murray M, Theron G, Udwadia Z, Migliori G, Warren R. 2014. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med 2:321–338. https://doi.org/10.1016/S2213-2600(14)70031-1.
228. Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M, PanACEA Consortium. 2017. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis 17:39–49. https://doi.org/10.1016/S1473-3099(16)30274-2.
229. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR, Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM. 2017. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med 5:291–360. https://doi.org/10.1016/S2213-2600(17)30079-6.
230. Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. 2018. Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov 17:35–56. https://doi.org/10.1038/nrd.2017.162.
231. World Health Organization. 2011. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. World Health Organization, Geneva, Switzerland.
232. Anonymous. 2016. Using biomarkers to predict TB treatment duration. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02821832 (registration number NCT02821832). Accessed 17 January 2018.
233. Cohen T, Lipsitch M, Walensky RP, Murray M. 2006. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci U S A 103:7042–7047. https://doi.org/10.1073/pnas.0600349103.
234. Kunkel A, Colijn C, Lipsitch M, Cohen T. 2015. How could preventive therapy affect the prevalence of drug resistance? Causes and consequences. Philos Trans R Soc Lond B Biol Sci 370:20140306. https://doi.org/10.1098/rstb.2014.0306.
235. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. 2006. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 12:744–751. https://doi.org/10.3201/eid1205.050681.
236. Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via LE, Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE, III, Winter J, Walzl G, Lucas L, Spuy GV, Stanley K, Thiart L, Smith B, Du Plessis N, Beltran CG, Maasdorp E, Ellmann A, Choi H, Joh J, Dodd LE, Allwood B, Koegelenberg C, Vorster M, Griffith-Richards S. 2016. Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat Med 22:1094–1100. https://doi.org/10.1038/nm.4177.
237. Rakotosamimanana N, Raharimanga V, Andriamandimby SF, Soares JL, Doherty TM, Ratsitorahina M, Ramarokoto H, Zumla A, Huggett J, Rook G, Richard V, Gicquel B, Rasolofo-Razanamparany V. 2010. Variation in gamma interferon responses to different infecting strains of Mycobacterium tuberculosis in acid-fast bacillus smear-positive patients and household contacts in Antananarivo, Madagascar. Clin Vaccine Immunol 17:1094–1103. https://doi.org/10.1128/CVI.00049-10.
238. Kong Y, Cave MD, Zhang L, Foxman B, Marrs CF, Bates JH, Yang ZH. 2006. Population-based study of deletions in five different genomic regions of Mycobacterium tuberculosis and possible clinical relevance of the deletions. J Clin Microbiol 44:3940–3946. https://doi.org/10.1128/JCM.01146-06.
239. Lan NTN, Lien HTK, Tung LB, Borgdorff MW, Kremer K, van Soolingen D. 2003. Mycobacterium tuberculosis Beijing genotype and risk for treatment failure and relapse, Vietnam. Emerg Infect Dis 9:1633–1635. https://doi.org/10.3201/eid0912.030169.
240. Sun YJ, Lee AS, Wong SY, Paton NI. 2006. Association of Mycobacterium tuberculosis Beijing genotype with tuberculosis relapse in Singapore. Epidemiol Infect 134:329–332. https://doi.org/10.1017/S095026880500525X.
241. Parwati I, Alisjahbana B, Apriani L, Soetikno RD, Ottenhoff TH, van der Zanden AG, van der Meer J, van Soolingen D, van Crevel R. 2010. Mycobacterium tuberculosis Beijing genotype is an independent risk factor for tuberculosis treatment failure in Indonesia. J Infect Dis 201: 553–557. https://doi.org/10.1086/650311.
242. van Crevel R, Nelwan RH, de Lenne W, Veeraragu Y, van der Zanden AG, Amin Z, van der Meer JW, van Soolingen D. 2001. Mycobacterium tuberculosis Beijing genotype strains associated with febrile response to treatment. Emerg Infect Dis 7:880–883. https://doi.org/10.3201/eid0705.017518.
243. Lari N, Rindi L, Cristofani R, Rastogi N, Tortoli E, Garzelli C. 2009. Association of Mycobacterium tuberculosis complex isolates of BOVIS and Central Asian (CAS) genotypic lineages with extrapulmonary disease. Clin Microbiol Infect 15:538–543. https://doi.org/10.1111/j.1469-0691.2009.02712.x.
244. Caws M, Thwaites G, Dunstan S, Hawn TR, Lan NT, Thuong NT, Stepniewska K, Huyen MN, Bang ND, Loc TH, Gagneux S, van Soolingen D, Kremer K, van der Sande M, Small P, Anh PT, Chinh NT, Quy HT, Duyen NT, Tho DQ, Hieu NT, Torok E, Hien TT, Dung NH, Nhu NT, Duy PM, van Vinh Chau N, Farrar J. 2008. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog 4:e1000034. https://doi.org/10.1371/journal.ppat.1000034.
245. Thwaites G, Caws M, Chau TT, D’Sa A, Lan NT, Huyen MN, Gagneux S, Anh PT, Tho DQ, Torok E, Nhu NT, Duyen NT, Duy PM, Richenberg J, Simmons C, Hien TT, Farrar J. 2008. Relationship between Mycobacterium tuberculosis genotype and the clinical phenotype of pulmonary and meningeal tuberculosis. J Clin Microbiol 46:1363–1368. https://doi.org/10.1128/JCM.02180-07.
246. Yimer SA, Norheim G, Namouchi A, Zegeye ED, Kinander W, Tonjum T, Bekele S, Mannsaker T, Bjune G, Aseffa A, Holm-Hansen C. 2015. Mycobacterium tuberculosis lineage 7 strains are associated with prolonged patient delay in seeking treatment for pulmonary tuberculosis in Amhara Region, Ethiopia. J Clin Microbiol 53:1301–1309. https://doi.org/10.1128/JCM.03566-14.
247. Carmona J, Cruz A, Moreira-Teixeira L, Sousa C, Sousa J, Osorio NS, Saraiva AL, Svenson S, Kallenius G, Pedrosa J, Rodrigues F, Castro AG, Saraiva M. 2013. Mycobacterium tuberculosis strains are differentially recognized by TLRs with an impact on the immune response. PLoS One 8:e67277. https://doi.org/10.1371/journal.pone.0067277.
248. Reyes-Martinez JE, Nieto-Patlan E, Nieto-Patlan A, Gonzaga-Bernachi J, Santos-Mendoza T, Serafin-Lopez J, Chavez-Blanco A, Sandoval-Montes C, Flores-Romo L, Estrada-Parra S, Estrada-Garcia I, Chacon-Salinas R. 2014. Differential activation of dendritic cells by Mycobacterium tuberculosis Beijing genotype. Immunol Invest 43:436–446. https://doi.org/10.3109/08820139.2014.880120.
249. Ordway D, Henao-Tamayo M, Harton M, Palanisamy G, Troudt J, Shan-ley C, Basaraba RJ, Orme IM. 2007. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J Immunol 179:522–531. https://doi.org/10.4049/jimmunol.179.1.522.